KIF5B/RET is an abnormal gene that leads to the growth of lung cancer cells. Cabozantinib is an investigational drug that inhibits the effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.

In this study, researchers are evaluating the safety and effectiveness of cabozantinib in patients with advanced non-small cell lung cancers that contain the KIF5B/RET gene. Cabozantinib is a pill that is taken orally (by mouth).